Background: Porphyria comprises a group of metabolic disorders caused by the irregular activities of enzymes within the haem biosynthetic pathway. This disease can provoke a large variety of symptoms. Acute porphyria attacks need to be treated urgently to avoid prolonged illness and fatal complications. Haem arginate, a concentrated haem solution stabilized with arginine, is the only preparation available for treatment in Europe and South America. This report describes a safe desensitization protocol for patients who require such treatment and have haem arginate hypersensitivity.
Case Presentation: A 25-year-old female patient diagnosed with acute intermittent porphyria, who had an anaphylactic reaction while receiving haem arginate. The patient was treated with a desensitization protocol for patients with hypersensitivity to haem arginate.
Conclusion: Porphyria is a disease that can significantly compromise a patient's quality of life. The desensitization protocol for patients with hypersensitivity to haem arginate is a safe and effective treatment option for patients with a history of haem arginate allergies, to whom it is not possible to administer haematin.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439413 | PMC |
| http://dx.doi.org/10.1016/j.waojou.2018.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute Intermittent Porphyria: A Diagnostic Conundrum.
Cureus
October 2024
Internal Medicine, ABLE Charitable Hospital, Bahrola, IND.
Article Synopsis
- A 20-year-old female presented with severe abdominal pain, nausea, and discolored urine, and was diagnosed with acute intermittent porphyria (AIP) after initial tests showed no abnormalities but later revealed elevated urinary porphobilinogen.
- Her medical history included recurrent urinary tract infections, a past episode of SIADH, and psychiatric issues like anxiety and depression.
- The patient received targeted treatment, including intravenous Haem arginate, leading to improvement, but she required further hospitalization due to symptom recurrence, emphasizing the need for better awareness and education regarding AIP in Acute Medicine.
Teaching an old drug new tricks: Regulatory insights for the repurposing of hemin in cardiovascular disease.
Pharmacol Res Perspect
August 2024
Department of Pharmacology, Dalhousie University, Saint John, New Brunswick, Canada.
Drug repurposing has gained significant interest in recent years due to the high costs associated with de novo drug development; however, comprehensive pharmacological information is needed for the translation of pre-existing drugs across clinical applications. In the present study, we explore the current pharmacological understanding of the orphan drug, hemin, and identify remaining knowledge gaps with regard to hemin repurposing for the treatment of cardiovascular disease. Originally approved by the United States Food and Drug Administration in 1983 for the treatment of porphyria, hemin has attracted significant interest for therapeutic repurposing across a variety of pathophysiological conditions.
View Article and Find Full Text PDFLong-term management and treatment of acute intermittent porphyria with recurring attacks using pharmacological prophylaxis.
Hepatol Commun
December 2023
Department of Pharmacy, Chang Gung Memorial Hospital Linkou Medical Centre, Taoyuan, Taiwan.
Background: There is no definitive guidance on whether patients with acute intermittent porphyria (AIP) with recurrent attacks need pharmacological prophylactic treatment.
Methods: The management strategies for patients with frequent (defined as ≥4 annualized attack rate (AAR) and less frequent attacks (<4 AAR), including treatment for acute attacks and duration of prophylaxis (weekly heme arginate 3 mg/kg body weight and/or investigational drug, givosiran), were summarized. The AAR for the following periods were presented: the first 2 years after diagnosis, before/after prophylaxis, and the most recent 2 years.
[Acute hepatic porphyrias].
Med Klin Intensivmed Notfmed
February 2023
Medizinische Klinik I, Allgemeine Innere Medizin, Universitätsklinikum Schleswig-Holstein Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.
Acute porphyrias are caused by rare hereditary disorders of hepatic heme biosynthesis. Episodes of accumulating neurotoxic metabolites lead to multisystemic symptoms such as visceral pain, autonomic dysregulation, neurocognitive impairment, hyponatremia, and occasionally motor paralysis. In addition to protracted non-emergency courses, acute life-threatening crises can occur, often triggered by infection, medication, fasting, or hormonal stimuli.
View Article and Find Full Text PDFReversible Cerebral Vasospasm in Acute Intermittent Porphyria: A Case Report and Review of the Literature.
Eur J Case Rep Intern Med
September 2022
Internal Medicine Unit, Pellegrin Teaching Hospital, Bordeaux, France.
Unlabelled: The porphyrias are rare inherited diseases of heme biosynthesis which can involve the nervous system. The most common neurological manifestations of acute intermittent porphyria are autonomic visceral neuropathy, peripheral motor neuropathy, and central nervous system dysfunction. In rare cases, patients with acute intermittent porphyria have presented with cerebral infarction, suggested to be due to vasospasm in cerebral arteries.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!